Market Overview

Xenon Pharmaceuticals Q4 Earnings Outlook


Xenon Pharmaceuticals (NASDAQ: XENE) unveils its next round of earnings Wednesday. Get prepared with Benzinga's ultimate preview for Xenon Pharmaceuticals' Q4 earnings.

Earnings and Revenue

Analysts covering Xenon Pharmaceuticals have modeled for quarterly EPS loss of 11 cents on revenue of $6.28 million.

Xenon Pharmaceuticals reported a loss of 32 cents per share when it published results during the same quarter last year. Sales in that period totaled $376,000. If the company were to report inline earnings when it publishes results Wednesday, quarterly profit would be up 65 percent.

Here's how the company's EPS has stacked up against analyst estimates in the past:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.08 -0.39 -0.38 -0.42
EPS Actual -0.43 -0.41 -0.43 -0.32


Stock Performance

Over the last 52-week period, shares are down 53.78 percent. Given that these returns are generally negative, long-term shareholders won't be happy going into this earnings release. Long-term shareholders are already enjoying 12-month gains prior to the announcement.

Analyst estimates are adjusted higher for EPS and revenues over the past 90 days. The most common rating by analysts on Xenon Pharmaceuticals stock is a Buy. The strength of this rating has maintained conviction over the past three months.

Conference Call

Xenon Pharmaceuticals's Q4 conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (XENE)

View Comments and Join the Discussion!

GBP/USD Forecast: Pound Pressured Under $1.3900 By Another EU Draft, Trump's Trade Tariffs

A Preview Of Collegium Pharmaceutical Q4 Earnings